Recently, we had the privilege of having John F. Crowley, President and CEO of the Biotechnology Innovation Organization, join us at our offices and the ClinImmune Cell & Gene Therapy labs. John spoke with RheumaGen CEO Richard Freed to discuss our mission to engineer a cure for #autoimmue diseases. Watch below!
RheumaGen
生物技术研究
Denver，Colorado 563 位关注者
RheumaGen is engineering a cure for autoimmune diseases.
关于我们
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.
- 网站
-
https://www.rheumagen.com
RheumaGen的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Denver，Colorado
- 类型
- 私人持股
- 创立
- 2019
- 领域
- Gene Therapy
地点
-
主要
获取路线
200 Quebec St
205
US，Colorado，Denver，80230
RheumaGen员工
动态
-
Great interview by our CSO and lead inventor Brian Freed. Thanks to Medscape for sharing our approach!
We’re excited to share that our Co-founder and Chief Scientific Officer, Brian Freed, Ph.D., was featured in a Medscape article, discussing RheumaGen’s novel approach to treating #RheumatoidArthritis and other #autoimmune diseases through HLA-gene modification. Read it here: https://wb.md/4h0D6mz
-
-
We’re excited to share that our Co-founder and Chief Scientific Officer, Brian Freed, Ph.D., was featured in a Medscape article, discussing RheumaGen’s novel approach to treating #RheumatoidArthritis and other #autoimmune diseases through HLA-gene modification. Read it here: https://wb.md/4h0D6mz
-
-
Thank you, Colorado BioScience Association, for hosting a lively roundtable discussion with Rep. Diana DeGette (D-CO) and John F. Crowley, President & CEO of Biotechnology Innovation Organization (BIO), at ClinImmune Cell & Gene Therapy?on the?University of Colorado Anschutz Medical Campus and Fitzsimons Innovation Community?campus earlier this week. RheumaGen?CEO?and Co-Founder, Richard Freed, was happy to provide our esteemed guests with a tour of the labs and share an overview of RheumaGen and our goal to cure autoimmune diseases like #RA. ? #COBioScience #BIOontheAmericanRoad
Colorado BioScience Association was honored to welcome Rep. Diana DeGette (D-CO) and John F. Crowley, President & CEO of Biotechnology Innovation Organization (BIO), to a roundtable discussion and tour at the ClinImmune Cell & Gene Therapy labs at Fitzsimons Innovation Community, adjacent to the University of Colorado Anschutz Medical Campus.?Congresswoman DeGette emphasized the bipartisan, bicameral commitment to biomedical research, saying, “disease impacts every family in America.” She urged scientists and researchers to speak out when their research is impacted by policy decisions. Richard Freed, President & CEO of RheumaGen, a Colorado company developing a new class of HLA gene-editing therapies for major autoimmune diseases in the ClinImmune labs, told the audience his company is seeking cures for diseases like rheumatoid arthritis. BIO President & CEO John Crowley called the current era “the golden age of medicine” and indicated ~70% of the medicines developed in the U.S. come from innovative startups like RheumaGen. He emphasized the importance of ?science and medicine to our health, the U.S. economy, and national security. Vineet Chopra, M.D., Chairman of the Department of Medicine, University of Colorado School of Medicine, spoke about the University's unwavering commitment to scientists and patients.?? #COBioScience?#StrongerTogether #AllIn #COHubforHealthImpact #BIOontheAmericanRoad
-
-
-
-
-
+4
-
-
We are excited to share the news that RheumaGen’s Scientific Advisor Board Member, Dr. Georg Schett, a luminary in the field of CAR T for autoimmune diseases, will present at the University of Colorado Anschutz Medical Campus’s Medicine Grand Rounds:?2024 Kroc Division Lectureship. Please tune in on Wednesday, February 5th at 2 p.m. ET/12 p.m. MT. Watch live with this link: https://lnkd.in/gTG9d9QV
-
-
RheumaGen转发了
Our client, RheumaGen, is kicking off the New Year with exciting news! Congratulations to the team on announcing their launch with the close of a $15 million Series A financing.
We are thrilled to announce our launch with a $15 million Series A financing. The financing will support RheumaGen in completing a Phase I clinical trial of its lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA). Read the full release:?https://lnkd.in/eB9ibY2S
-
-
We are thrilled to announce our launch with a $15 million Series A financing. The financing will support RheumaGen in completing a Phase I clinical trial of its lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA). Read the full release:?https://lnkd.in/eB9ibY2S
-